| Status | In progress |
| Process | HST |
| ID number | 1570 |
Provisional Schedule
| Committee meeting: 2 | 10 November 2021 |
| Expected publication | 26 January 2022 |
Project Team
| Project lead | Joanne Ekeledo |
Email enquiries
- If you have any queries please email HST@nice.org.uk
| Evidence Review Group / Assessment Group | School of Health and Related Research (ScHARR), University of Sheffield |
Consultees
| Companies sponsors | Albireo (obevixibat) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Children’s Liver Disease Foundation |
| Professional groups | British Association for the Study of the Liver |
| Royal College of Paediatrics and Child Health | |
| Royal College of Physicians |
Commentators
| Associated public health groups | None |
| Comparator companies | None |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 September 2021 - 07 October 2021 | Evaluation consultation: 1 |
| 05 August 2021 | Committee meeting: 1 |
| 02 March 2021 | Invitation to participate |
| 02 March 2021 | In progress. In progress |
| 15 July 2020 - 12 August 2020 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance